Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus

Carl E. Stafstrom; Herbert E. Gilmore; Paul S. Kurtin

doi:10.1016/0887-8994(92)90064-6

Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus

Carl E. Stafstrom, Herbert E. Gilmore, Paul S. Kurtin

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Furosemide and acetazolamide are often used concurrently to treat posthemorrhagic hydrocephalus in premature infants with intraventricular hemorrhage. Eleven premature infants with posthemorrhagic hydrocephalus were monitored for the development of hypercalciuria during treatment using urine calcium/creatinine (Ca/Cr) ratios (normal: ≤ 0.21). Seven of 11 infants (64%) developed hypercalciuria; 5 of those 7 infants had nephrocalcinosis on renal ultrasonography. Infants who developed nephrocalcinosis had urine Ca/Cr ratios of 0.5-4.0. In all 5 infants with nephrocalcinosis, renal calculi decreased and urine Ca/Cr improved after drug therapy was discontinued. The combined use of acetazolamide and furosemide as therapy for posthemorrhagic hydrocephalus places premature infants at high risk for nephrocalcinosis. It is suggested that urine Ca/Cr be monitored closely in infants receiving these drugs and that other treatment modalities be considered when the urine Ca/Cr ratio exceeds 0.21.

Original language	English (US)
Pages (from-to)	179-182
Number of pages	4
Journal	Pediatric Neurology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/0887-8994(92)90064-6
State	Published - Jan 1 1992
Externally published	Yes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Neurology
Developmental Neuroscience
Clinical Neurology

Access to Document

10.1016/0887-8994(92)90064-6

Cite this

@article{4818b06843f747f0aedf4807d664497e,

title = "Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus",

abstract = "Furosemide and acetazolamide are often used concurrently to treat posthemorrhagic hydrocephalus in premature infants with intraventricular hemorrhage. Eleven premature infants with posthemorrhagic hydrocephalus were monitored for the development of hypercalciuria during treatment using urine calcium/creatinine (Ca/Cr) ratios (normal: ≤ 0.21). Seven of 11 infants (64%) developed hypercalciuria; 5 of those 7 infants had nephrocalcinosis on renal ultrasonography. Infants who developed nephrocalcinosis had urine Ca/Cr ratios of 0.5-4.0. In all 5 infants with nephrocalcinosis, renal calculi decreased and urine Ca/Cr improved after drug therapy was discontinued. The combined use of acetazolamide and furosemide as therapy for posthemorrhagic hydrocephalus places premature infants at high risk for nephrocalcinosis. It is suggested that urine Ca/Cr be monitored closely in infants receiving these drugs and that other treatment modalities be considered when the urine Ca/Cr ratio exceeds 0.21.",

author = "Stafstrom, {Carl E.} and Gilmore, {Herbert E.} and Kurtin, {Paul S.}",

year = "1992",

month = jan,

day = "1",

doi = "10.1016/0887-8994(92)90064-6",

language = "English (US)",

volume = "8",

pages = "179--182",

journal = "Pediatric Neurology",

issn = "0887-8994",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus

AU - Stafstrom, Carl E.

AU - Gilmore, Herbert E.

AU - Kurtin, Paul S.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Furosemide and acetazolamide are often used concurrently to treat posthemorrhagic hydrocephalus in premature infants with intraventricular hemorrhage. Eleven premature infants with posthemorrhagic hydrocephalus were monitored for the development of hypercalciuria during treatment using urine calcium/creatinine (Ca/Cr) ratios (normal: ≤ 0.21). Seven of 11 infants (64%) developed hypercalciuria; 5 of those 7 infants had nephrocalcinosis on renal ultrasonography. Infants who developed nephrocalcinosis had urine Ca/Cr ratios of 0.5-4.0. In all 5 infants with nephrocalcinosis, renal calculi decreased and urine Ca/Cr improved after drug therapy was discontinued. The combined use of acetazolamide and furosemide as therapy for posthemorrhagic hydrocephalus places premature infants at high risk for nephrocalcinosis. It is suggested that urine Ca/Cr be monitored closely in infants receiving these drugs and that other treatment modalities be considered when the urine Ca/Cr ratio exceeds 0.21.

AB - Furosemide and acetazolamide are often used concurrently to treat posthemorrhagic hydrocephalus in premature infants with intraventricular hemorrhage. Eleven premature infants with posthemorrhagic hydrocephalus were monitored for the development of hypercalciuria during treatment using urine calcium/creatinine (Ca/Cr) ratios (normal: ≤ 0.21). Seven of 11 infants (64%) developed hypercalciuria; 5 of those 7 infants had nephrocalcinosis on renal ultrasonography. Infants who developed nephrocalcinosis had urine Ca/Cr ratios of 0.5-4.0. In all 5 infants with nephrocalcinosis, renal calculi decreased and urine Ca/Cr improved after drug therapy was discontinued. The combined use of acetazolamide and furosemide as therapy for posthemorrhagic hydrocephalus places premature infants at high risk for nephrocalcinosis. It is suggested that urine Ca/Cr be monitored closely in infants receiving these drugs and that other treatment modalities be considered when the urine Ca/Cr ratio exceeds 0.21.

UR - http://www.scopus.com/inward/record.url?scp=0026719107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026719107&partnerID=8YFLogxK

U2 - 10.1016/0887-8994(92)90064-6

DO - 10.1016/0887-8994(92)90064-6

M3 - Article

C2 - 1622512

AN - SCOPUS:0026719107

SN - 0887-8994

VL - 8

SP - 179

EP - 182

JO - Pediatric Neurology

JF - Pediatric Neurology

IS - 3

ER -

Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this